Physician profile
Edwin E Young
NPI 1437130366
$7,973.51
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,237 · 2020: $2,258 · 2021: $2,478.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,730.81 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $851.03 | 2019-2021 | |
| Pfizer INC. | $715.78 | 2019-2021 | |
| Lilly USA, LLC | $571.93 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $505.68 | 2019-2021 | |
| Novo Nordisk INC | $500.44 | 2019-2021 | |
| Amarin Pharma, INC. | $404.72 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $353.33 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $343.47 | 2019-2021 | |
| Glaxosmithkline, LLC. | $315.34 | 2019-2021 | |
| Amgen INC. | $247.63 | 2019-2021 | |
| Astellas Pharma US INC | $185.80 | 2019-2020 | |
| Allergan, INC. | $183.61 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $177.49 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $127.51 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $126.96 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $118.09 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.36 | 2019 | |
| Sunovion Pharmaceuticals INC. | $82.82 | 2021 | |
| Abbvie INC. | $77.45 | 2021 | |
| Vanda Pharmaceuticals INC. | $57.56 | 2021 | |
| Jazz Pharmaceuticals INC. | $56.29 | 2020-2021 | |
| Endo Pharmaceuticals INC. | $34.07 | 2019 | |
| Sanofi Pasteur INC. | $29.09 | 2019-2020 | |
| Almatica Pharma LLC | $27.59 | 2021 | |
| Mylan Specialty L.P. | $24.15 | 2021 | |
| Redhill Biopharma INC. | $20.39 | 2020 | |
| Abbott Laboratories | $18.12 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.